{"id":4924,"date":"2013-01-25T10:13:00","date_gmt":"2013-01-25T07:13:00","guid":{"rendered":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2026\/01\/19\/sut-komisyonu-calismasi\/"},"modified":"2026-01-19T11:09:57","modified_gmt":"2026-01-19T08:09:57","slug":"sut-komisyonu-calismasi","status":"publish","type":"post","link":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/","title":{"rendered":"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI"},"content":{"rendered":"
\n

 <\/p>\n

\n SUT KOM\u0130SYONU \u00c7ALI\u015eMASI<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n Pratik Bilgiler:<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n Plavix tb:<\/span><\/b> G\u0130S \u0130ntolerans\u0131 ibaresi kald\u0131r\u0131ld\u0131. KAH tan\u0131s\u0131nda Anjio \u015fart\u0131 devam etmektedir.<\/span>\n<\/div>\n
\n Mide ila\u00e7lar\u0131: <\/span><\/b>14 tb\u2019lik formundan 2 kutu yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi zorunlulu\u011fu devam etmektedir. 30 tb lik olanlar devam re\u00e7etelerinde \u00f6denir. Bu devam re\u00e7etesinin, ilk al\u0131mdaki ila\u00e7 bitim tarihinden sonra 3 ay i\u00e7ersinde olmal\u0131d\u0131r. <\/span>\n<\/div>\n
\n Anemi ila\u00e7lar\u0131:<\/span><\/b> Bir kutudan fazla yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi istenmektedir.<\/span>\n<\/div>\n
\n Altuzan Amp<\/span><\/b>: Ok\u00fcler neovask\u00fclarizasyonlar ve t\u00fcm makulopati veya retinopatilerde periok\u00fcler veya intraok\u00fcler olarak endikasyonu olmad\u0131\u011f\u0131 halde kullan\u0131labilmektedir.(Endikasyan D\u0131\u015f\u0131 ila\u00e7 Kullan\u0131m duyurusu)<\/span>\n<\/div>\n
\n Zofran tb<\/span><\/b> : Yatan Hastalarda \u00f6denir. Ayaktan Sadece Kanser veya Kan Hastal\u0131klar\u0131(alt ba\u015fl\u0131klar dahil) raporu ile \u00f6denir.<\/span>\n<\/div>\n
\n Risperdal amp<\/span><\/b>: Sadece yatan hastalarda Psikiyatri uzman\u0131nca veya yine bu uzman hekimin bulundu\u011fu sa\u011fl\u0131k kurulu raporuyla.<\/span>\n<\/div>\n
\n Helicol 15 mg 30 tb<\/span><\/b>: ilk defa kullan\u0131ld\u0131\u011f\u0131nda \u00f6denmez. Devam re\u00e7etelerinde rapor \u015fart\u0131 aranmaks\u0131z\u0131n Helicol 15 mg 30 tb \u00f6denir.<\/span>\n<\/div>\n
\n Piogtan 30 mg 30 tb<\/span><\/b>:\u0130lk defa re\u00e7ete edildi\u011finde 28 tb lik e\u015fde\u011feri oldu\u011fundan \u00f6denmez. Ancak devam re\u00e7etesinde ila\u00e7 bitiminden sonra 3 ay i\u00e7ersinde hasta taraf\u0131ndan re\u00e7ete edildi\u011finde Piogtan 30 mg 30 tb lik \u00f6denir.<\/span>\n<\/div>\n
\n Sevk \u0130\u015flemi:<\/b>Kurum Mart 2013 itibariyle e-sevk uygulamas\u0131na ge\u00e7ecektir. Kurum duyuru yap\u0131ncaya kadar sevk \u00f6rne\u011finin bir n\u00fcshas\u0131 al\u0131nacakt\u0131r.\n<\/div>\n
\n E-Sevk i\u015flemlerinde uygulamaya ge\u00e7i\u015fte ya\u015fanabilecek olas\u0131 s\u0131k\u0131nt\u0131lar\u0131n \u00f6nlenmesi i\u00e7in sa\u011fl\u0131k hizmeti sunucular\u0131n\u0131n a\u015fa\u011f\u0131da belirtilen hususlara dikkat etmesi gerekmektedir. <\/span>\n<\/div>\n
\n M\u00fcstahakl\u0131k sorgulamas\u0131 60\/c-1, 60\/c-3 veya 60\/c-9 bilgisi d\u00f6nen hastalar ile Sa\u011fl\u0131k Uygulama Tebli\u011finde sa\u011fl\u0131k hizmeti sunucular\u0131na m\u00fcracaat i\u00e7in sevk zinciri tan\u0131mlanm\u0131\u015f ki\u015filerin sevk i\u015flemlerinde, sisteme entegrasyonu sa\u011flan\u0131ncaya kadar \u00f6nceki uygulamalara devam edilecektir.<\/span>\n<\/div>\n
\n Enbrel,Leponex tb,Roaccutan: <\/span><\/b>Kurum taraf\u0131ndan yap\u0131lacak olan duyuruya kadar Enbrel i\u00e7in hasta onaylama formu ile G\u00fcvenlik izlem formu re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecek. Leponex i\u00e7in Gran\u00fclosit izlem formu(L\u00f6kosite bak\u0131lm\u0131\u015f olan) ve Roacccutan i\u00e7in hasta onaylama formlar\u0131 re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecektir.<\/span>\n<\/div>\n
\n Enfeksiyon Hastal\u0131klar\u0131 Uzaman\u0131\u0131 onay\u0131: <\/span><\/b>Hastanenin kendi i\u00e7 sistemiyle ilgili olup hen\u00fcz medullada g\u00f6r\u00fcnmemektedir. Kurum gerekli duyuruyu yap\u0131ncaya kadar Ma\u011fduriyet olu\u015fmamas\u0131 i\u00e7in dikkat edilmesi gerekmektedir.<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 10.01.2013 Tarihli SUT De\u011fi\u015fikli\u011fi<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n 1)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.1.4- 5.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) : Yan\u0131klar, anemiler, sistemik olmayan mantar enfeksiyonlar\u0131, refl\u00fc ve GIS \u00fclserlerinde kullan\u0131lan ila\u00e7lar; yaln\u0131z dermatoloji uzman hekimlerince re\u00e7ete edilebilen oral retinoidler, taburcu edilen hastalar\u0131n idame tedavisi i\u00e7in d\u00fczenlenen re\u00e7etelere yaz\u0131lan ila\u00e7lar, en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir.<\/span><\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 6.1.4- 8.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla <\/span>28 g\u00fcnl\u00fck doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir.<\/span><\/span>\n<\/div>\n
\n Not: Bir ila\u00e7 ilk defa re\u00e7ete edildi\u011finde, ilac\u0131n veya e\u015fde\u011firinin k\u00fc\u00e7\u00fck formunun verilmesine dikkat ediniz. Ancak tedavi \u015femas\u0131nda fazla say\u0131da i\u00e7eren ilac\u0131n kullan\u0131m\u0131nda, 28 g\u00fcnl\u00fck dozu ge\u00e7miyor ise yine verilebilir. Paxil 56 tb 2*1 den 56 tb lik form \u00f6denir. Paxil 56 tb 1*1 \u015feklinde yaz\u0131l\u0131 ise 28 tb lik formu \u00f6denir. Devam re\u00e7etelerinde ise 28 g\u00fcnl\u00fck k\u0131s\u0131tlamas\u0131 yoktur. \u00d6rnek olarak piogtan 30 mg 30 tb ilk defa hasta kullanacak ise e\u015fde\u011fi olan actos 30 mg 28 tb verilmelidir. Devam\u0131nda ise piogtan 30 mg 30 tb 3 ayl\u0131k 01.02.2013 tarihinden itibaren ise 6 ayl\u0131k verilebilir. Rapor yenilenmesinde ilac\u0131n dozunda de\u011fi\u015fiklik yok ise devam gibi kabul edilir 3 ayl\u0131k veya a\u015fa\u011f\u0131da belirtilen hastal\u0131klarda 6 ayl\u0131k alabilir.<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n  \n<\/div>\n
\n  \n<\/div>\n
\n  \n<\/div>\n
\n  \n<\/div>\n
\n  \n<\/div>\n
\n 2)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.1.5- 9.F\u0131kraEklenmi\u015ftir (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013)<\/span>\n<\/div>\n
\n \u201c(9) Yeniden e-re\u00e7ete d\u00fczenlenmeksizin yap\u0131lacak ila\u00e7 temininde;<\/span>\n<\/div>\n
\n a) SUT eki \u201cHasta Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar Listesi\u2019nde (EK-2) yer alan hastal\u0131klardan a\u015fa\u011f\u0131da belirtilen hastal\u0131k gruplar\u0131 ile bu hastal\u0131k gruplar\u0131 i\u00e7in EK-2 listesinde tan\u0131ml\u0131 ila\u00e7lar uygulama kapsam\u0131ndad\u0131r.<\/span>\n<\/div>\n
\n 1- (4.1.) Kalp Yetmezli\u011fi (I50) <\/span>\n<\/div>\n
\n 2- (4.2.) Koroner Arter Hastal\u0131\u011f\u0131 (I20) (I25) (Z95.1) (Z95.5-Z95.9) <\/span>\n<\/div>\n
\n 3- (4.5.) Arteriyel hipertansiyon (I10 -I13) (I15) <\/span>\n<\/div>\n
\n 4- (4.8.) Hiperkolesterolemi*, hiperlipidemi * (E78) <\/span>\n<\/div>\n
\n 5- (7.2.1.) Diabetes Mellitus (E10 \u2013 E14) <\/span>\n<\/div>\n
\n 6- (10.3.1.) Parkinson hastal\u0131\u011f\u0131 (G20) <\/span>\n<\/div>\n
\n 7- (10.7.) Demans (F00) (F01.1 \u2013 F01.9) (F02-F03) (G30) <\/span>\n<\/div>\n
\n 8- (12.1.) Glokom (H40.1-H40.9) <\/span>\n<\/div>\n
\n 9- (12.2) Kronik ve n\u00fckseden \u00fcveitler, tiroide ba\u011fl\u0131 oftalmopati ve sempatik oftalmi, keratoplasti red reaksiyonu (H20.1) (H20.8) (H06.2) (H44.1) (T86.8-T86.9) <\/span>\n<\/div>\n
\n 10- (12.3.) Kuru g\u00f6z sendromu (H04.1) <\/span>\n<\/div>\n
\n b) Yukar\u0131da belirtilen hastal\u0131klarda sa\u011fl\u0131k raporuna dayan\u0131larak d\u00fczenlenmi\u015f re\u00e7eteye istinaden yeniden re\u00e7ete d\u00fczenlenmeksizin eczaneden ila\u00e7 temin edilebilir. Bu \u015fekilde ila\u00e7 temini, d\u00fczenlenmi\u015f re\u00e7ete tarihi itibariyle <\/span>6 ayl\u0131k s\u00fcreyi kapsar. S\u00fcre bitiminde tekrar re\u00e7ete d\u00fczenlenir.<\/span><\/span>\n<\/div>\n
\n c) 6 ay boyunca, d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 miktarlar esas al\u0131narak, yeniden re\u00e7ete d\u00fczenlenmeksizin bu miktarlarda ila\u00e7 temin edilebilir. Ancak SUT \u2019ta belirtilen \u00f6zel h\u00fck\u00fcmler ile d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 g\u00fcnl\u00fck kullan\u0131m dozuna g\u00f6re bir seferde \u00fc\u00e7 ayl\u0131k tedavi dozunun a\u015f\u0131lmamas\u0131 g\u00f6zetilir.<\/span>\n<\/div>\n
\n \u00e7) Raporun ge\u00e7erlilik s\u00fcresinin bitmesi durumunda yeniden rapor ve re\u00e7ete d\u00fczenlenmesi \u015fart\u0131 aran\u0131r.\u201d<\/span>\n<\/div>\n
\n Not: b ve C maddelerine dikkat edilirse, 6 ayl\u0131k doz ile 3 ayl\u0131k doz uygulamalar\u0131n\u0131 g\u00f6rmekteyiz. 6 ayl\u0131k doz uygulamas\u0131 sadece yukar\u0131da belirtilen hastal\u0131klarda uygulanacakt\u0131r. Rapor tarihi ila\u00e7 verilme tarihinden sonra 6 aydan \u00f6nce bitiyor ise bu s\u00fcreye kadar verilir. Dikkat edilmesi gereken di\u011fer husus ise; bir ilac\u0131n 28 g\u00fcnl\u00fck dozundan 3 ayl\u0131k 4 kutu yaz\u0131lm\u0131\u015f ise 3 kutu yerine 4 kutu da verilebilme imkan\u0131n\u0131n sa\u011flanmas\u0131d\u0131r. Singulair 28 tb 1*1 den rapor s\u00fcresi dahilinde 4 kutu \u00f6denir. <\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n 3)<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n 6.2.2- 2. ve 3.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) <\/span>\n<\/div>\n
\n \u201c(2) Yeni nesil (atipik) antipsikotiklerin (klozapin, olanzapin, risperidon, amis\u00fclpirid, ketiapin, ziprosidon, aripiprazol, zotepine, Sertindol, paliperidon ) ve kombinasyonlar\u0131n\u0131n oral formlar\u0131, psikiyatri veya n\u00f6roloji uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenecek uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Klozapin en fazla 1 ayl\u0131k dozda re\u00e7ete edilebilir.<\/span>\n<\/div>\n
\n (3) Yeni nesil (atipik) antipsikotiklerin parenteral formlar\u0131 psikiyatri uzman hekimi veya bu uzman hekim taraf\u0131ndan d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Bu grup antipsikotiklerden risperidon ve paliperidonun parenteral formlar\u0131 ise Ek:2\/B h\u00fck\u00fcmlerine g\u00f6re re\u00e7ete edilebilir.\u201d<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n Not: Klozapin (Leponex)<\/span><\/b> : En fazla bir ayl\u0131k doz olmas\u0131na ve Klozapin Gran\u00fclosit izlem formunun e-re\u00e7etede belirtilmesine dikkat edilmelidir.<\/b><\/span>\n<\/div>\n
\n 4)<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n 6.2.9.A -1De\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) <\/span>\n<\/div>\n
\n Eritropoietin alfa-beta-zeta, metoksipolietilen glikol epoetin beta ve darbepoetin ile tedaviye ba\u015flamadan \u00f6nce; hastan\u0131n ferritin ve\/veya transferrin saturasyonu (TSAT) de\u011ferlerine bak\u0131lacakt\u0131r. Bu de\u011ferler TSAT < %20 ve\/veya ferritin <100 \u00b5g\/L ise hastaya \u00f6ncelikle oral veya intraven\u00f6z demir tedavisine ba\u015flanacakt\u0131r. TSAT \u2265 %20 ve\/veya ferritin \u2265 100 \u00b5g\/L oldu\u011funda hemoglobin de\u011feri 10 gr\/dl alt\u0131nda ise tedaviye ba\u015flan\u0131r. Hedef hemoglobin de\u011feri 11-12 gr\/dl aras\u0131d\u0131r. Hemoglobin de\u011feri 11 gr\/dl’ye ula\u015f\u0131ncaya kadar ba\u015flang\u0131\u00e7 dozunda tedaviye devam edilir ve Hb seviyesini 11-12 gr\/dl aras\u0131nda tutabilmek i\u00e7in idame dozda tedaviye devam edilir. Hb seviyesi 12 gr\/dl’yi a\u015f\u0131nca tedavi kesilir. Hasta Hb seviyesi i\u00e7in takibe al\u0131nacak ve Hb seviyesi 11-12 gr\/dl\u2019nin aras\u0131na gelince hastaya idame dozda tedaviye tekrar ba\u015flanabilir. \u0130dame tedavi s\u0131ras\u0131nda ve\/veya tedaviye yeniden ba\u015fland\u0131\u011f\u0131nda TSAT >%20 ve\/veya ferritin >100 \u00b5g\/L olmal\u0131d\u0131r. Bu de\u011ferlere hemodiyaliz hastalar\u0131nda 3 ayda bir, periton diyaliz hastalar\u0131nda 4 ayda bir bak\u0131l\u0131r ve tetkik sonu\u00e7 belgesinin tarihi ve sonucu re\u00e7etede belirtilir. Tetkik sonu\u00e7lar\u0131n\u0131n cihaz \u00e7\u0131kt\u0131s\u0131 \u015feklinde olmas\u0131 \u015fart olup, el yaz\u0131s\u0131 ile yaz\u0131lan sonu\u00e7lar dikkate al\u0131nmaz.\u201d<\/span>\n<\/div>\n
\n MADDE 8 \u2013 Ayn\u0131 Tebli\u011fin 6.2.9.A-2 numaral\u0131 maddesinin birinci f\u0131kras\u0131 a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span>\n<\/div>\n
\n \u201c(1) Hemoglobin de\u011feri 11 gr\/dl’nin, blast oran\u0131 %5\u2019in ve serum eritropoietin d\u00fczeyi 500mu\/ml\u2019nin alt\u0131nda olan hastalarda tedaviye ba\u015flan\u0131r. Hedef hemoglobin de\u011feri 12 gr\/dl\u2019dir. Hb seviyesi 12 gr\/dl\u2019yi a\u015f\u0131nca tedavi kesilir. Maksimum doz haftada 900 IU\/kg\u2019\u0131 a\u015fmamal\u0131d\u0131r. Eritropoietin alfa-beta ve darbepoetin, hematoloji uzman hekimi taraf\u0131ndan d\u00fczenlenen uzman hekim raporuna dayan\u0131larak, hematoloji veya i\u00e7 hastal\u0131klar\u0131 uzman hekimlerince re\u00e7ete edilebilir. Hemogram sonu\u00e7 belgesi tarihi ve sonucu re\u00e7etede belirtilir.\u201d<\/span>\n<\/div>\n
\n MADDE 9 \u2013 Ayn\u0131 Tebli\u011fin 6.2.9.B numaral\u0131 maddesi a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span>\n<\/div>\n
\n \u201c6.2.9.B \u2013 Sevelamer ve al\u00fcminyum klor\u00fcr hidroksit kullan\u0131m ilkeleri<\/span>\n<\/div>\n
\n (1) Tedaviye ba\u015flamak i\u00e7in di\u011fer fosfor d\u00fc\u015f\u00fcr\u00fcc\u00fc ila\u00e7lar\u0131n en az 3 ay s\u00fcreyle kullan\u0131lm\u0131\u015f olmas\u0131 ve bu hususun raporda belirtilmi\u015f olmas\u0131 gerekir. Bu s\u00fcre sonunda:<\/span>\n<\/div>\n
\n a) Kalsiyum ve fosfor \u00e7arp\u0131m\u0131 72 ve \u00fczerinde olan veya<\/span>\n<\/div>\n
\n b) PTH d\u00fczeyinin 100 pg\/ml de\u011ferinin alt\u0131nda olan adinamik kemik hastal\u0131\u011f\u0131 olgular\u0131 veya<\/span>\n<\/div>\n
\n c) Hastan\u0131n Kt\/V de\u011feri 1.4\u2019\u00fcn \u00fczerinde olmas\u0131na ra\u011fmen d\u00fczeltilmi\u015f kalsiyum ve fosfor \u00e7arp\u0131m\u0131 55\u2019in \u00fczerinde olan veya<\/span>\n<\/div>\n
\n \u00e7) Kt\/V de\u011feri 1.4’\u00fcn \u00fczerinde olan hastan\u0131n PTH de\u011feri 300 pg\/ml ve \u00fczerinde olan, hastalarda tedaviye ba\u015flan\u0131r.<\/span>\n<\/div>\n
\n (2) Hemodiyaliz veya periton diyaliz tedavisi alt\u0131ndaki hastalara nefroloji veya diyaliz sertifikal\u0131 i\u00e7 hastal\u0131klar\u0131\/\u00e7ocuk sa\u011fl\u0131\u011f\u0131 ve hastal\u0131klar\u0131 uzman hekimlerinden birinin d\u00fczenledi\u011fi ve yukar\u0131daki durumlardan sevelamer veya al\u00fcminyum klor\u00fcr hidroksit kullan\u0131m\u0131n\u0131 gerektiren durumun belirtildi\u011fi uzman hekim raporuna dayan\u0131larak bu hekimlerce veya diyaliz sertifikal\u0131 t\u00fcm hekimler taraf\u0131ndan re\u00e7ete edildi\u011finde bedeli \u00f6denir.<\/span>\n<\/div>\n
\n (3) Her re\u00e7etede fosfor d\u00fczeyini g\u00f6sterir son 1 ay i\u00e7inde yap\u0131lm\u0131\u015f tetkik sonu\u00e7 belgesinin tarihi ve sonucu belirtilir. Bir defada en fazla (birer ayl\u0131k dozda) bir kutu ila\u00e7 verilir. Fosfor d\u00fczeyi 3.5mg\/dl’nin alt\u0131nda oldu\u011fu durumlarda tedavi kesilir.<\/span>\n<\/div>\n
\n (4) Fosfor d\u00fczeyinin 3.5mg\/dl’nin \u00fczerine \u00e7\u0131kmas\u0131 durumunda tedaviye ilk ba\u015flama kriterleri aranarak tekrar ba\u015flanabilir.\u201d<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n NOT: 6.2.9.A-1 de belirtilen <\/span><\/b>\n<\/div>\n
\n TSAT, Ferritin, Hemoglobin(Hgb) de\u011ferlerine:<\/span><\/b>\n<\/div>\n
\n Hemodiyaliz hastalar\u0131na 3 ayda bir<\/span><\/b>\n<\/div>\n
\n Periton diyaliz hastalar\u0131na 4 ayda bir<\/span><\/b>\n<\/div>\n
\n 6.2.9.B de belirtilen fosfor d\u00fczeyine 1 ay i\u00e7inde yap\u0131lm\u0131\u015f olmas\u0131 gerekmektedir. Sevelamer(Renagel) ve Al\u00fcminyum klor\u00fcr Hidroksit bir defada en fazla 1 ayl\u0131k tedavi dozunda yaz\u0131l\u0131r.<\/span><\/b>\n<\/div>\n
\n Hemoglobin de\u011feri 10gr\/dl alt\u0131nda tedaviye ba\u015flan\u0131r ve 12gr\/dl oldu\u011funda ise tedavi kesilir.<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 5)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.2.13.E-2(Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) numaral\u0131 maddesine a\u015fa\u011f\u0131daki alt\u0131nc\u0131 f\u0131kra eklenmi\u015ftir.<\/span><\/span>\n<\/div>\n
\n \u201c(6) Kompanse sirozu olan genotip I hastalarda (karaci\u011fer biyopsisinde ISHAK skoruna g\u00f6re evre 4 ve \u00fczerinde olanlar veya trombosit say\u0131s\u0131 100.000 alt\u0131nda olanlarda veya protrombin zaman\u0131 kontrol\u00fcn 3 saniye \u00fczerinde olanlar) <\/span>peginterferon + ribavirin + telaprevir<\/span> tedavisi ba\u015flanabilir. Tedavi s\u00fcresi 48 haftad\u0131r. Telaprevir 12 haftadan daha uzun s\u00fcre kullan\u0131lamaz.\u201d<\/span>\n<\/div>\n
\n  <\/span>6.2.13.E-3(Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013)  numaral\u0131 maddesinin ikinci ve \u00fc\u00e7\u00fcnc\u00fc f\u0131kras\u0131 a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span><\/span>\n<\/div>\n
\n \u201c(2) \u0130nterferon veya pegileinterferon monoterapisi alan ve cevaps\u0131z olan hastalarda tedavi almam\u0131\u015f hastalar ile ayn\u0131 kurallara tabi olarak pegileinterferon + ribavirin tedavisi verilebilir.<\/span>\n<\/div>\n
\n (3) \u0130nterferon + ribavirin veya pegileinterferon + ribavirin tedavisine cevap veren ancak n\u00fcks etmi\u015f (tedavi bitiminde HCV RNA (-) olan ancak izleminde HCV RNA yeniden pozitifle\u015fen) hastalarda bir defaya mahsus olmak \u00fczere a\u015fa\u011f\u0131daki tedavi \u015femalar\u0131ndan yaln\u0131zca biri kullan\u0131labilir.<\/span>\n<\/div>\n
\n a) Yeniden interferon + ribavirin veya pegileinterferon + ribavirin tedavisi alabilirler. 16. haftadan sonra tedavinin s\u00fcrd\u00fcr\u00fclebilmesi i\u00e7in 12. haftada bak\u0131lan HCV RNA (-) ya da 2 log (100 kat) azalm\u0131\u015f olmal\u0131d\u0131r. Tedavi s\u00fcresi 48 haftay\u0131 ge\u00e7emez.<\/span>\n<\/div>\n
\n b) <\/span>Pegileinterferon + ribavirin + telaprevir<\/span> (\u00fc\u00e7l\u00fc) tedavisi alabilirler. Bu hastalarda tedavinin 4. haftas\u0131nda HCV RNA bak\u0131l\u0131r.<\/span>\n<\/div>\n
\n 1- Tedavinin 4. haftas\u0131nda bak\u0131lan HCV RNA (-) ise \u00fc\u00e7l\u00fc tedavi 12 haftaya, devam\u0131nda pegileinterferon + ribavirin ile tedavi toplam 24 haftaya tamamlan\u0131r.<\/span>\n<\/div>\n
\n 2- Tedavinin 4. haftas\u0131nda bak\u0131lan HCV RNA (+) ise \u00fc\u00e7l\u00fc tedavi 12 haftaya, devam\u0131nda pegileinterferon + ribavirin ile tedavi toplam 48 haftaya tamamlan\u0131r. Ancak tedaviye ba\u015fland\u0131ktan sonra 12. hafta sonunda HCV RNA d\u00fczeyleri 2 log (100 kat) azalmayanlarda tedavi s\u00fcresi 16 haftay\u0131 ge\u00e7emez. 24. haftada HCV RNA pozitifli\u011fi devam eden hastalarda tedavi en ge\u00e7 28. hafta sonunda kesilir.\u201d<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 6)<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n 6.2.15.A \u2013 Klopidogrel (kombinasyonlar\u0131 dahil) Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013<\/span>\n<\/div>\n
\n b) \u00dc\u00e7\u00fcnc\u00fc f\u0131kras\u0131 a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span>\n<\/div>\n
\n \u201c(3) Kalp kapak biyoprotezi bulunanlarda, anjiografik olarak belgelenmi\u015f koroner arter hastal\u0131\u011f\u0131, t\u0131kay\u0131c\u0131 periferik arter hastal\u0131\u011f\u0131 veya serebral iskemik olay (iskemik inme) saptanan hastalarda, kardiyoloji, i\u00e7 hastal\u0131klar\u0131, n\u00f6roloji, kalp damar cerrahisi veya acil t\u0131p uzman hekimlerinden biri taraf\u0131ndan d\u00fczenlenen ve 12 ay\u0131 ge\u00e7memek \u00fczere kullan\u0131m s\u00fcresinin belirtildi\u011fi uzman hekim raporu ile di\u011fer hekimler taraf\u0131ndan da re\u00e7ete edilebilir. Raporun yenilenmesi halinde yukar\u0131da belirtilen hususlar ge\u00e7erlidir.\u201d<\/span>\n<\/div>\n
\n NOT:G\u0130S \u0130ntolerans\u0131 ibaresi bu tarih itibariyle istenmeyecektir. Asprin ile birlikte kullan\u0131m\u0131nda ise art\u0131k kesinti olmayacakt\u0131r.<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 7)<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n  6.2.15.C (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) : Ivabradin(Coralan tb) <\/span>\n<\/div>\n
\n  numaral\u0131 maddesine a\u015fa\u011f\u0131daki ikinci f\u0131kra eklenmi\u015ftir.<\/span>\n<\/div>\n
\n \u201c(2) Kronik kalp yetmezli\u011fi tedavisinde ejeksiyon fraksiyonu %45 in alt\u0131nda olan hastalarda a\u015fa\u011f\u0131daki durumlarda en az bir kardiyoloji uzman hekiminin bulundu\u011fu sa\u011fl\u0131k kurulu raporu ile kardiyoloji veya i\u00e7 hastal\u0131klar\u0131 uzman hekimleri taraf\u0131ndan re\u00e7ete edilebilir;<\/span>\n<\/div>\n
\n a) Beta blok\u00f6r tedavisi alt\u0131nda olup halen kalp h\u0131z\u0131 y\u00fcksek seyreden veya<\/span>\n<\/div>\n
\n b) Beta blok\u00f6r kontrendikasyonu olan veya<\/span>\n<\/div>\n
\n c) Beta blok\u00f6r tedavisine intolerans\u0131 olan.\u201d<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 8)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.2.17.A<\/span>(Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 16.01.2013) numaral\u0131 maddesinin birinci ve ikinci f\u0131kras\u0131 a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span><\/span>\n<\/div>\n
\n \u201c(1) Osteoporoz tedavisinde bifosfonatlar (kombinasyonlar\u0131 dahil) ve di\u011fer osteoporoz ila\u00e7lar\u0131 (raloksifen, calcitonin, stronsiyum ranelat) a\u015fa\u011f\u0131da belirtilen ko\u015fullar \u00e7er\u00e7evesinde \u00f6denir. Bu ila\u00e7lar tedavi s\u00fcresinin belirtildi\u011fi sa\u011fl\u0131k raporuna dayan\u0131larak re\u00e7ete edilirler. Rapor s\u00fcresi 1 y\u0131ld\u0131r. Bu grup ila\u00e7lar\u0131n birlikte kombine kullan\u0131m\u0131 halinde sadece birinin bedeli \u00f6denir.<\/span>\n<\/div>\n
\n (2) Osteoporozda ila\u00e7 tedavisi, d\u00fczenlenecek rapor tarihinden \u00f6nce son bir y\u0131l i\u00e7inde yap\u0131lan KMY \u00f6l\u00e7\u00fcm\u00fcyle planlan\u0131r. \u00d6l\u00e7\u00fcm en erken 1 y\u0131l sonra tekrar edilebilir ve y\u0131lda bir defadan daha s\u0131k yap\u0131lamaz. KMY \u00f6l\u00e7\u00fcm\u00fcn\u00fcn tarihi ve sonucu re\u00e7ete veya raporda belirtilir. KMY \u00f6l\u00e7\u00fcm\u00fc bir kal\u00e7as\u0131nda protez olan hastada di\u011fer kal\u00e7adan, her iki kal\u00e7as\u0131nda da protez olan hastada vertebra ya da \u00f6n koldan yap\u0131labilir.\u201d<\/span>\n<\/div>\n
\n NOT: KMY \u00d6l\u00e7\u00fcm belgesinin sonu\u00e7lar\u0131 e-re\u00e7ete veya e-raporda belirtilmelidir<\/span><\/b>.<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 9)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.2.28.A<\/span>(Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013)  numaral\u0131 maddesinin ba\u015fl\u0131\u011f\u0131 a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span><\/span>\n<\/div>\n
\n 6.2.28.A \u2013 Statinler (antihipertansiflerle kombinasyonlar\u0131 dahil) \u201d<\/span>\n<\/div>\n
\n Not: Daha \u00f6nceki de\u011fi\u015fiklikte statinler diye ba\u015flad\u0131\u011f\u0131ndan bu madde yukar\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 10) <\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.2.32.Kontrast maddeler(Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013)  <\/span><\/span>\n<\/div>\n
\n (4) Gadobutrol: Sadece karaci\u011fer ve b\u00f6brek manyetik rezonans incelemelerinde kullan\u0131l\u0131r.<\/span>\n<\/div>\n
\n NOT:Gadovist bu iki te\u015fhis d\u0131\u015f\u0131nda \u00f6denmez.<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 11)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n 6.2.33.1. (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013)   Ya\u015f tip ya\u015fa ba\u011fl\u0131 makula dejenerasyonunda kullan\u0131lan ila\u00e7lar\u0131n kullan\u0131m ilkeleri<\/span><\/span>\n<\/div>\n
\n (1) Pegaptanib Sodyum, Ranibizumab ve Vertaporfin etken maddelerini i\u00e7eren ila\u00e7lar; 3. basamak sa\u011fl\u0131k tesislerinde en az \u00fc\u00e7 g\u00f6z hastal\u0131klar\u0131 uzman\u0131n\u0131n yer ald\u0131\u011f\u0131 sa\u011fl\u0131k kurulu raporu ile hasta anamnezi, FFA ve lezyona ait renkli resim varl\u0131\u011f\u0131 raporda belirtilerek, g\u00f6z hastal\u0131klar\u0131 uzmanlar\u0131nca re\u00e7etelenerek uygulan\u0131r.<\/span>\n<\/div>\n
\n (2) Ranibizumab; hasta anamnezi, FFA ve lezyona ait renkli resim varl\u0131\u011f\u0131na ait bilgiler 3 ay s\u00fcreli sa\u011fl\u0131k kurulu raporunda belirtilerek birer ay arayla 3 kez y\u00fckleme dozuyla ba\u015flan\u0131r. Hastalar izlenerek g\u00f6z dibi bulgular\u0131, g\u00f6rme keskinli\u011fi ve optik koherens tomografileri (OKT) de\u011ferlendirilir ve tekrar tedavi gerekirse bu bulgular ve tedaviye devam karar\u0131 her uygulama i\u00e7in d\u00fczenlenecek yeni sa\u011fl\u0131k kurulu raporunda belirtilir.<\/span>\n<\/div>\n
\n (3) Bu grup ila\u00e7lar ard\u0131\u015f\u0131k ya da kombine olarak kullan\u0131lamayacakt\u0131r.<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n (4) Bu grup ila\u00e7lar 1.1.2011 tarihinden itibaren yaln\u0131zca ayaktan tedavi kapsam\u0131nda \u00f6denecektir (Depocu sat\u0131\u015f fiyatl\u0131 \u00fcr\u00fcnler hari\u00e7).\u201d<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n NOT: FFA ve lezyona ait resimler e-raporda varl\u0131\u011f\u0131 belirtilecektir.<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 12)<\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n  Venofer, Ferroven amp. V.b. (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013)   <\/span><\/span>\n<\/div>\n
\n  \n<\/div>\n
\n 6.2.41 numaral\u0131 maddesinin birinci f\u0131kras\u0131na a\u015fa\u011f\u0131daki d\u00fczenlemeler 8, 9, 10, 11, 12, 13 ve 14 \u00fcnc\u00fc alt madde olarak eklenmi\u015ftir.<\/span>\n<\/div>\n
\n \u201c8-Demir eksikli\u011fi anemisi bulunan (saturasyon <\/span>\n<\/div>\n
\n 9-Periton diyaliz hastalar\u0131n\u0131n anemisi,<\/span>\n<\/div>\n
\n 10-Postpartum d\u00f6nemde g\u00f6zlenen anemi,<\/span>\n<\/div>\n
\n 11-Cerrahi \u00f6ncesi ve sonras\u0131 g\u00f6zlenen anemi,<\/span>\n<\/div>\n
\n 12-Kansere ba\u011fl\u0131 anemi,<\/span>\n<\/div>\n
\n 13-KKY hastalar\u0131n\u0131n anemisi,<\/span>\n<\/div>\n
\n 14-Prediyaliz (hemodiyaliz ve periton diyaliz \u00f6ncesi son d\u00f6nem [evre V] KBY hastalar\u0131) hastalar\u0131n\u0131n anemisi,\u201d<\/span>\n<\/div>\n
\n Not: Daha \u00f6nce a\u015fa\u011f\u0131daki te\u015fhislerde \u00f6denen bu ila\u00e7lara \u00f6denmesine yukar\u0131da belirtilen endikasyonlardada \u00f6denmeye ba\u015flam\u0131\u015ft\u0131r.<\/span><\/b>\n<\/div>\n
\n (1) Parenteral demir preparatlar\u0131 a\u015fa\u011f\u0131da yer alan durumlarda bu durumlar\u0131n belirtildi\u011fi uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilir.<\/span>\n<\/div>\n
\n 1-      \u0130ntestinal malabsorbsiyon sendromlar\u0131<\/span>\n<\/div>\n
\n 2-      Kronik inflamatuvar ba\u011f\u0131rsak hastal\u0131klar\u0131 <\/span>\n<\/div>\n
\n 3-      Aktif GIS kanamas\u0131 olan hastalar<\/span>\n<\/div>\n
\n 4-      Hemodiyaliz hastalar\u0131<\/span>\n<\/div>\n
\n 5-      Total ve subtotal gastrektomili hastalar <\/span>\n<\/div>\n
\n 6-      Atrofik gastritli hastalar<\/span>\n<\/div>\n
\n 7-      Oral demir al\u0131m\u0131n\u0131 tolere edemeyen hamileler<\/span>\n<\/div>\n
\n 13) <\/span><\/b>\n<\/div>\n
\n  \n<\/div>\n
\n Ayakta Tedavide Sa\u011fl\u0131k Raporu (Uzman Hekim Raporu\/Sa\u011fl\u0131k Kurulu Raporu) ile Verilebilecek \u0130la\u00e7lar Listesi\u201d nde (Ek-2\/C) a\u015fa\u011f\u0131daki de\u011fi\u015fiklikler yap\u0131lm\u0131\u015ft\u0131r.<\/span>\n<\/div>\n
\n a) (11) inci madde a\u015fa\u011f\u0131daki \u015fekilde de\u011fi\u015ftirilmi\u015ftir.<\/span>\n<\/div>\n
\n \u201c11.Palonosetron HCL (her k\u00fcr i\u00e7in bir flakon), Granisetron<\/span>(KYTR\u0130L, SETRON), Ondansetron<\/span>(ZOFRAN), Tropisetron<\/span>(NAVOBAN)<\/span>\n<\/div>\n
\n  \n<\/div>\n
\n  \n<\/div>\n
\n  \n<\/div>\n
\n SUT Komisyonu<\/span><\/u><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n Ecz.Mustafa KUTLUO\u011eLU<\/span><\/b>\n<\/div>\n
\n Ecz.\u015eevket HAMAV\u0130O\u011eLU<\/span><\/b>\n<\/div>\n
\n Ecz.C\u00fcneyd YAVUZ<\/span><\/b>\n<\/div>\n
\n Ecz.M.Ali \u00dc\u00c7K\u00d6K<\/span><\/b>\n<\/div>\n
\n Ecz.Servet KILI\u00c7<\/span><\/b>\n<\/div>\n
\n Ecz.M.Umut AKINCI<\/span><\/b>\n<\/div>\n
\n  <\/b>\n<\/div>\n
\n SUT Komisyonu Koordinat\u00f6r\u00fc : Ecz.Mehmet F\u0130TK\u0130<\/span><\/b>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

  SUT KOM\u0130SYONU \u00c7ALI\u015eMASI   Pratik Bilgiler:   Plavix tb: G\u0130S \u0130ntolerans\u0131 ibaresi kald\u0131r\u0131ld\u0131. KAH tan\u0131s\u0131nda Anjio \u015fart\u0131 devam etmektedir. Mide ila\u00e7lar\u0131: 14 tb\u2019lik formundan 2 kutu yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi zorunlulu\u011fu devam etmektedir. 30 tb lik olanlar devam re\u00e7etelerinde \u00f6denir. Bu devam re\u00e7etesinin, ilk al\u0131mdaki ila\u00e7 bitim tarihinden sonra 3 ay i\u00e7ersinde olmal\u0131d\u0131r. Anemi ila\u00e7lar\u0131: Bir kutudan fazla yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi istenmektedir. Altuzan Amp: Ok\u00fcler neovask\u00fclarizasyonlar ve t\u00fcm makulopati veya retinopatilerde periok\u00fcler veya intraok\u00fcler olarak endikasyonu olmad\u0131\u011f\u0131 halde kullan\u0131labilmektedir.(Endikasyan D\u0131\u015f\u0131 ila\u00e7 Kullan\u0131m duyurusu) Zofran tb : Yatan Hastalarda \u00f6denir. Ayaktan Sadece Kanser veya Kan Hastal\u0131klar\u0131(alt ba\u015fl\u0131klar dahil) raporu ile \u00f6denir. Risperdal amp: Sadece yatan hastalarda Psikiyatri uzman\u0131nca veya yine bu uzman hekimin bulundu\u011fu sa\u011fl\u0131k kurulu raporuyla. Helicol 15 mg 30 tb: ilk defa kullan\u0131ld\u0131\u011f\u0131nda \u00f6denmez. Devam re\u00e7etelerinde rapor \u015fart\u0131 aranmaks\u0131z\u0131n Helicol 15 mg 30 tb \u00f6denir. Piogtan 30 mg 30 tb:\u0130lk defa re\u00e7ete edildi\u011finde 28 tb lik e\u015fde\u011feri oldu\u011fundan \u00f6denmez. Ancak devam re\u00e7etesinde ila\u00e7 bitiminden sonra 3 ay i\u00e7ersinde hasta taraf\u0131ndan re\u00e7ete edildi\u011finde Piogtan 30 mg 30 tb lik \u00f6denir. Sevk \u0130\u015flemi:Kurum Mart 2013 itibariyle e-sevk uygulamas\u0131na ge\u00e7ecektir. Kurum duyuru yap\u0131ncaya kadar sevk \u00f6rne\u011finin bir n\u00fcshas\u0131 al\u0131nacakt\u0131r. E-Sevk i\u015flemlerinde uygulamaya ge\u00e7i\u015fte ya\u015fanabilecek olas\u0131 s\u0131k\u0131nt\u0131lar\u0131n \u00f6nlenmesi i\u00e7in sa\u011fl\u0131k hizmeti sunucular\u0131n\u0131n a\u015fa\u011f\u0131da belirtilen hususlara dikkat etmesi gerekmektedir. M\u00fcstahakl\u0131k sorgulamas\u0131 60\/c-1, 60\/c-3 veya 60\/c-9 bilgisi d\u00f6nen hastalar ile Sa\u011fl\u0131k Uygulama Tebli\u011finde sa\u011fl\u0131k hizmeti sunucular\u0131na m\u00fcracaat i\u00e7in sevk zinciri tan\u0131mlanm\u0131\u015f ki\u015filerin sevk i\u015flemlerinde, sisteme entegrasyonu sa\u011flan\u0131ncaya kadar \u00f6nceki uygulamalara devam edilecektir. Enbrel,Leponex tb,Roaccutan: Kurum taraf\u0131ndan yap\u0131lacak olan duyuruya kadar Enbrel i\u00e7in hasta onaylama formu ile G\u00fcvenlik izlem formu re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecek. Leponex i\u00e7in Gran\u00fclosit izlem formu(L\u00f6kosite bak\u0131lm\u0131\u015f olan) ve Roacccutan i\u00e7in hasta onaylama formlar\u0131 re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecektir. Enfeksiyon Hastal\u0131klar\u0131 Uzaman\u0131\u0131 onay\u0131: Hastanenin kendi i\u00e7 sistemiyle ilgili olup hen\u00fcz medullada g\u00f6r\u00fcnmemektedir. Kurum gerekli duyuruyu yap\u0131ncaya kadar Ma\u011fduriyet olu\u015fmamas\u0131 i\u00e7in dikkat edilmesi gerekmektedir.   10.01.2013 Tarihli SUT De\u011fi\u015fikli\u011fi   1)   6.1.4- 5.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) : Yan\u0131klar, anemiler, sistemik olmayan mantar enfeksiyonlar\u0131, refl\u00fc ve GIS \u00fclserlerinde kullan\u0131lan ila\u00e7lar; yaln\u0131z dermatoloji uzman hekimlerince re\u00e7ete edilebilen oral retinoidler, taburcu edilen hastalar\u0131n idame tedavisi i\u00e7in d\u00fczenlenen re\u00e7etelere yaz\u0131lan ila\u00e7lar, en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir.   6.1.4- 8.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. Not: Bir ila\u00e7 ilk defa re\u00e7ete edildi\u011finde, ilac\u0131n veya e\u015fde\u011firinin k\u00fc\u00e7\u00fck formunun verilmesine dikkat ediniz. Ancak tedavi \u015femas\u0131nda fazla say\u0131da i\u00e7eren ilac\u0131n kullan\u0131m\u0131nda, 28 g\u00fcnl\u00fck dozu ge\u00e7miyor ise yine verilebilir. Paxil 56 tb 2*1 den 56 tb lik form \u00f6denir. Paxil 56 tb 1*1 \u015feklinde yaz\u0131l\u0131 ise 28 tb lik formu \u00f6denir. Devam re\u00e7etelerinde ise 28 g\u00fcnl\u00fck k\u0131s\u0131tlamas\u0131 yoktur. \u00d6rnek olarak piogtan 30 mg 30 tb ilk defa hasta kullanacak ise e\u015fde\u011fi olan actos 30 mg 28 tb verilmelidir. Devam\u0131nda ise piogtan 30 mg 30 tb 3 ayl\u0131k 01.02.2013 tarihinden itibaren ise 6 ayl\u0131k verilebilir. Rapor yenilenmesinde ilac\u0131n dozunda de\u011fi\u015fiklik yok ise devam gibi kabul edilir 3 ayl\u0131k veya a\u015fa\u011f\u0131da belirtilen hastal\u0131klarda 6 ayl\u0131k alabilir.             2)   6.1.5- 9.F\u0131kraEklenmi\u015ftir (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) \u201c(9) Yeniden e-re\u00e7ete d\u00fczenlenmeksizin yap\u0131lacak ila\u00e7 temininde; a) SUT eki \u201cHasta Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar Listesi\u2019nde (EK-2) yer alan hastal\u0131klardan a\u015fa\u011f\u0131da belirtilen hastal\u0131k gruplar\u0131 ile bu hastal\u0131k gruplar\u0131 i\u00e7in EK-2 listesinde tan\u0131ml\u0131 ila\u00e7lar uygulama kapsam\u0131ndad\u0131r. 1- (4.1.) Kalp Yetmezli\u011fi (I50) 2- (4.2.) Koroner Arter Hastal\u0131\u011f\u0131 (I20) (I25) (Z95.1) (Z95.5-Z95.9) 3- (4.5.) Arteriyel hipertansiyon (I10 -I13) (I15) 4- (4.8.) Hiperkolesterolemi*, hiperlipidemi * (E78) 5- (7.2.1.) Diabetes Mellitus (E10 \u2013 E14) 6- (10.3.1.) Parkinson hastal\u0131\u011f\u0131 (G20) 7- (10.7.) Demans (F00) (F01.1 \u2013 F01.9) (F02-F03) (G30) 8- (12.1.) Glokom (H40.1-H40.9) 9- (12.2) Kronik ve n\u00fckseden \u00fcveitler, tiroide ba\u011fl\u0131 oftalmopati ve sempatik oftalmi, keratoplasti red reaksiyonu (H20.1) (H20.8) (H06.2) (H44.1) (T86.8-T86.9) 10- (12.3.) Kuru g\u00f6z sendromu (H04.1) b) Yukar\u0131da belirtilen hastal\u0131klarda sa\u011fl\u0131k raporuna dayan\u0131larak d\u00fczenlenmi\u015f re\u00e7eteye istinaden yeniden re\u00e7ete d\u00fczenlenmeksizin eczaneden ila\u00e7 temin edilebilir. Bu \u015fekilde ila\u00e7 temini, d\u00fczenlenmi\u015f re\u00e7ete tarihi itibariyle 6 ayl\u0131k s\u00fcreyi kapsar. S\u00fcre bitiminde tekrar re\u00e7ete d\u00fczenlenir. c) 6 ay boyunca, d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 miktarlar esas al\u0131narak, yeniden re\u00e7ete d\u00fczenlenmeksizin bu miktarlarda ila\u00e7 temin edilebilir. Ancak SUT \u2019ta belirtilen \u00f6zel h\u00fck\u00fcmler ile d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 g\u00fcnl\u00fck kullan\u0131m dozuna g\u00f6re bir seferde \u00fc\u00e7 ayl\u0131k tedavi dozunun a\u015f\u0131lmamas\u0131 g\u00f6zetilir. \u00e7) Raporun ge\u00e7erlilik s\u00fcresinin bitmesi durumunda yeniden rapor ve re\u00e7ete d\u00fczenlenmesi \u015fart\u0131 aran\u0131r.\u201d Not: b ve C maddelerine dikkat edilirse, 6 ayl\u0131k doz ile 3 ayl\u0131k doz uygulamalar\u0131n\u0131 g\u00f6rmekteyiz. 6 ayl\u0131k doz uygulamas\u0131 sadece yukar\u0131da belirtilen hastal\u0131klarda uygulanacakt\u0131r. Rapor tarihi ila\u00e7 verilme tarihinden sonra 6 aydan \u00f6nce bitiyor ise bu s\u00fcreye kadar verilir. Dikkat edilmesi gereken di\u011fer husus ise; bir ilac\u0131n 28 g\u00fcnl\u00fck dozundan 3 ayl\u0131k 4 kutu yaz\u0131lm\u0131\u015f ise 3 kutu yerine 4 kutu da verilebilme imkan\u0131n\u0131n sa\u011flanmas\u0131d\u0131r. Singulair 28 tb 1*1 den rapor s\u00fcresi dahilinde 4 kutu \u00f6denir.   3)   6.2.2- 2. ve 3.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) \u201c(2) Yeni nesil (atipik) antipsikotiklerin (klozapin, olanzapin, risperidon, amis\u00fclpirid, ketiapin, ziprosidon, aripiprazol, zotepine, Sertindol, paliperidon ) ve kombinasyonlar\u0131n\u0131n oral formlar\u0131, psikiyatri veya n\u00f6roloji uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenecek uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Klozapin en fazla 1 ayl\u0131k dozda re\u00e7ete edilebilir. (3) Yeni nesil (atipik) antipsikotiklerin parenteral formlar\u0131 psikiyatri uzman hekimi veya bu uzman hekim taraf\u0131ndan d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Bu grup antipsikotiklerden risperidon ve paliperidonun parenteral formlar\u0131 ise Ek:2\/B h\u00fck\u00fcmlerine g\u00f6re re\u00e7ete edilebilir.\u201d   Not: Klozapin (Leponex) : En fazla bir ayl\u0131k doz olmas\u0131na ve Klozapin Gran\u00fclosit izlem formunun e-re\u00e7etede belirtilmesine dikkat edilmelidir. 4)   6.2.9.A -1De\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Eritropoietin alfa-beta-zeta, metoksipolietilen glikol epoetin beta ve darbepoetin ile tedaviye ba\u015flamadan \u00f6nce; hastan\u0131n ferritin ve\/veya transferrin saturasyonu (TSAT) de\u011ferlerine bak\u0131lacakt\u0131r. Bu de\u011ferler TSAT < %20 ve\/veya ferritin <100 \u00b5g\/L ise hastaya \u00f6ncelikle oral veya intraven\u00f6z demir tedavisine ba\u015flanacakt\u0131r. TSAT \u2265 %20 ve\/veya ferritin \u2265 100 \u00b5g\/L oldu\u011funda hemoglobin de\u011feri 10 gr\/dl alt\u0131nda ise tedaviye ba\u015flan\u0131r. Hedef hemoglobin de\u011feri 11-12 gr\/dl aras\u0131d\u0131r. Hemoglobin de\u011feri 11 gr\/dl’ye ula\u015f\u0131ncaya kadar ba\u015flang\u0131\u00e7 dozunda tedaviye devam edilir ve Hb seviyesini<\/p>\n","protected":false},"author":4,"featured_media":191,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_canvas","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oda"],"yoast_head":"\nSUT KOM\u0130SYONU \u00c7ALI\u015eMASI - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"og:description\" content=\"  SUT KOM\u0130SYONU \u00c7ALI\u015eMASI   Pratik Bilgiler:   Plavix tb: G\u0130S \u0130ntolerans\u0131 ibaresi kald\u0131r\u0131ld\u0131. KAH tan\u0131s\u0131nda Anjio \u015fart\u0131 devam etmektedir. Mide ila\u00e7lar\u0131: 14 tb\u2019lik formundan 2 kutu yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi zorunlulu\u011fu devam etmektedir. 30 tb lik olanlar devam re\u00e7etelerinde \u00f6denir. Bu devam re\u00e7etesinin, ilk al\u0131mdaki ila\u00e7 bitim tarihinden sonra 3 ay i\u00e7ersinde olmal\u0131d\u0131r. Anemi ila\u00e7lar\u0131: Bir kutudan fazla yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi istenmektedir. Altuzan Amp: Ok\u00fcler neovask\u00fclarizasyonlar ve t\u00fcm makulopati veya retinopatilerde periok\u00fcler veya intraok\u00fcler olarak endikasyonu olmad\u0131\u011f\u0131 halde kullan\u0131labilmektedir.(Endikasyan D\u0131\u015f\u0131 ila\u00e7 Kullan\u0131m duyurusu) Zofran tb : Yatan Hastalarda \u00f6denir. Ayaktan Sadece Kanser veya Kan Hastal\u0131klar\u0131(alt ba\u015fl\u0131klar dahil) raporu ile \u00f6denir. Risperdal amp: Sadece yatan hastalarda Psikiyatri uzman\u0131nca veya yine bu uzman hekimin bulundu\u011fu sa\u011fl\u0131k kurulu raporuyla. Helicol 15 mg 30 tb: ilk defa kullan\u0131ld\u0131\u011f\u0131nda \u00f6denmez. Devam re\u00e7etelerinde rapor \u015fart\u0131 aranmaks\u0131z\u0131n Helicol 15 mg 30 tb \u00f6denir. Piogtan 30 mg 30 tb:\u0130lk defa re\u00e7ete edildi\u011finde 28 tb lik e\u015fde\u011feri oldu\u011fundan \u00f6denmez. Ancak devam re\u00e7etesinde ila\u00e7 bitiminden sonra 3 ay i\u00e7ersinde hasta taraf\u0131ndan re\u00e7ete edildi\u011finde Piogtan 30 mg 30 tb lik \u00f6denir. Sevk \u0130\u015flemi:Kurum Mart 2013 itibariyle e-sevk uygulamas\u0131na ge\u00e7ecektir. Kurum duyuru yap\u0131ncaya kadar sevk \u00f6rne\u011finin bir n\u00fcshas\u0131 al\u0131nacakt\u0131r. E-Sevk i\u015flemlerinde uygulamaya ge\u00e7i\u015fte ya\u015fanabilecek olas\u0131 s\u0131k\u0131nt\u0131lar\u0131n \u00f6nlenmesi i\u00e7in sa\u011fl\u0131k hizmeti sunucular\u0131n\u0131n a\u015fa\u011f\u0131da belirtilen hususlara dikkat etmesi gerekmektedir. M\u00fcstahakl\u0131k sorgulamas\u0131 60\/c-1, 60\/c-3 veya 60\/c-9 bilgisi d\u00f6nen hastalar ile Sa\u011fl\u0131k Uygulama Tebli\u011finde sa\u011fl\u0131k hizmeti sunucular\u0131na m\u00fcracaat i\u00e7in sevk zinciri tan\u0131mlanm\u0131\u015f ki\u015filerin sevk i\u015flemlerinde, sisteme entegrasyonu sa\u011flan\u0131ncaya kadar \u00f6nceki uygulamalara devam edilecektir. Enbrel,Leponex tb,Roaccutan: Kurum taraf\u0131ndan yap\u0131lacak olan duyuruya kadar Enbrel i\u00e7in hasta onaylama formu ile G\u00fcvenlik izlem formu re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecek. Leponex i\u00e7in Gran\u00fclosit izlem formu(L\u00f6kosite bak\u0131lm\u0131\u015f olan) ve Roacccutan i\u00e7in hasta onaylama formlar\u0131 re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecektir. Enfeksiyon Hastal\u0131klar\u0131 Uzaman\u0131\u0131 onay\u0131: Hastanenin kendi i\u00e7 sistemiyle ilgili olup hen\u00fcz medullada g\u00f6r\u00fcnmemektedir. Kurum gerekli duyuruyu yap\u0131ncaya kadar Ma\u011fduriyet olu\u015fmamas\u0131 i\u00e7in dikkat edilmesi gerekmektedir.   10.01.2013 Tarihli SUT De\u011fi\u015fikli\u011fi   1)   6.1.4- 5.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) : Yan\u0131klar, anemiler, sistemik olmayan mantar enfeksiyonlar\u0131, refl\u00fc ve GIS \u00fclserlerinde kullan\u0131lan ila\u00e7lar; yaln\u0131z dermatoloji uzman hekimlerince re\u00e7ete edilebilen oral retinoidler, taburcu edilen hastalar\u0131n idame tedavisi i\u00e7in d\u00fczenlenen re\u00e7etelere yaz\u0131lan ila\u00e7lar, en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir.   6.1.4- 8.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. Not: Bir ila\u00e7 ilk defa re\u00e7ete edildi\u011finde, ilac\u0131n veya e\u015fde\u011firinin k\u00fc\u00e7\u00fck formunun verilmesine dikkat ediniz. Ancak tedavi \u015femas\u0131nda fazla say\u0131da i\u00e7eren ilac\u0131n kullan\u0131m\u0131nda, 28 g\u00fcnl\u00fck dozu ge\u00e7miyor ise yine verilebilir. Paxil 56 tb 2*1 den 56 tb lik form \u00f6denir. Paxil 56 tb 1*1 \u015feklinde yaz\u0131l\u0131 ise 28 tb lik formu \u00f6denir. Devam re\u00e7etelerinde ise 28 g\u00fcnl\u00fck k\u0131s\u0131tlamas\u0131 yoktur. \u00d6rnek olarak piogtan 30 mg 30 tb ilk defa hasta kullanacak ise e\u015fde\u011fi olan actos 30 mg 28 tb verilmelidir. Devam\u0131nda ise piogtan 30 mg 30 tb 3 ayl\u0131k 01.02.2013 tarihinden itibaren ise 6 ayl\u0131k verilebilir. Rapor yenilenmesinde ilac\u0131n dozunda de\u011fi\u015fiklik yok ise devam gibi kabul edilir 3 ayl\u0131k veya a\u015fa\u011f\u0131da belirtilen hastal\u0131klarda 6 ayl\u0131k alabilir.             2)   6.1.5- 9.F\u0131kraEklenmi\u015ftir (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) \u201c(9) Yeniden e-re\u00e7ete d\u00fczenlenmeksizin yap\u0131lacak ila\u00e7 temininde; a) SUT eki \u201cHasta Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar Listesi\u2019nde (EK-2) yer alan hastal\u0131klardan a\u015fa\u011f\u0131da belirtilen hastal\u0131k gruplar\u0131 ile bu hastal\u0131k gruplar\u0131 i\u00e7in EK-2 listesinde tan\u0131ml\u0131 ila\u00e7lar uygulama kapsam\u0131ndad\u0131r. 1- (4.1.) Kalp Yetmezli\u011fi (I50) 2- (4.2.) Koroner Arter Hastal\u0131\u011f\u0131 (I20) (I25) (Z95.1) (Z95.5-Z95.9) 3- (4.5.) Arteriyel hipertansiyon (I10 -I13) (I15) 4- (4.8.) Hiperkolesterolemi*, hiperlipidemi * (E78) 5- (7.2.1.) Diabetes Mellitus (E10 \u2013 E14) 6- (10.3.1.) Parkinson hastal\u0131\u011f\u0131 (G20) 7- (10.7.) Demans (F00) (F01.1 \u2013 F01.9) (F02-F03) (G30) 8- (12.1.) Glokom (H40.1-H40.9) 9- (12.2) Kronik ve n\u00fckseden \u00fcveitler, tiroide ba\u011fl\u0131 oftalmopati ve sempatik oftalmi, keratoplasti red reaksiyonu (H20.1) (H20.8) (H06.2) (H44.1) (T86.8-T86.9) 10- (12.3.) Kuru g\u00f6z sendromu (H04.1) b) Yukar\u0131da belirtilen hastal\u0131klarda sa\u011fl\u0131k raporuna dayan\u0131larak d\u00fczenlenmi\u015f re\u00e7eteye istinaden yeniden re\u00e7ete d\u00fczenlenmeksizin eczaneden ila\u00e7 temin edilebilir. Bu \u015fekilde ila\u00e7 temini, d\u00fczenlenmi\u015f re\u00e7ete tarihi itibariyle 6 ayl\u0131k s\u00fcreyi kapsar. S\u00fcre bitiminde tekrar re\u00e7ete d\u00fczenlenir. c) 6 ay boyunca, d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 miktarlar esas al\u0131narak, yeniden re\u00e7ete d\u00fczenlenmeksizin bu miktarlarda ila\u00e7 temin edilebilir. Ancak SUT \u2019ta belirtilen \u00f6zel h\u00fck\u00fcmler ile d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 g\u00fcnl\u00fck kullan\u0131m dozuna g\u00f6re bir seferde \u00fc\u00e7 ayl\u0131k tedavi dozunun a\u015f\u0131lmamas\u0131 g\u00f6zetilir. \u00e7) Raporun ge\u00e7erlilik s\u00fcresinin bitmesi durumunda yeniden rapor ve re\u00e7ete d\u00fczenlenmesi \u015fart\u0131 aran\u0131r.\u201d Not: b ve C maddelerine dikkat edilirse, 6 ayl\u0131k doz ile 3 ayl\u0131k doz uygulamalar\u0131n\u0131 g\u00f6rmekteyiz. 6 ayl\u0131k doz uygulamas\u0131 sadece yukar\u0131da belirtilen hastal\u0131klarda uygulanacakt\u0131r. Rapor tarihi ila\u00e7 verilme tarihinden sonra 6 aydan \u00f6nce bitiyor ise bu s\u00fcreye kadar verilir. Dikkat edilmesi gereken di\u011fer husus ise; bir ilac\u0131n 28 g\u00fcnl\u00fck dozundan 3 ayl\u0131k 4 kutu yaz\u0131lm\u0131\u015f ise 3 kutu yerine 4 kutu da verilebilme imkan\u0131n\u0131n sa\u011flanmas\u0131d\u0131r. Singulair 28 tb 1*1 den rapor s\u00fcresi dahilinde 4 kutu \u00f6denir.   3)   6.2.2- 2. ve 3.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) \u201c(2) Yeni nesil (atipik) antipsikotiklerin (klozapin, olanzapin, risperidon, amis\u00fclpirid, ketiapin, ziprosidon, aripiprazol, zotepine, Sertindol, paliperidon ) ve kombinasyonlar\u0131n\u0131n oral formlar\u0131, psikiyatri veya n\u00f6roloji uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenecek uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Klozapin en fazla 1 ayl\u0131k dozda re\u00e7ete edilebilir. (3) Yeni nesil (atipik) antipsikotiklerin parenteral formlar\u0131 psikiyatri uzman hekimi veya bu uzman hekim taraf\u0131ndan d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Bu grup antipsikotiklerden risperidon ve paliperidonun parenteral formlar\u0131 ise Ek:2\/B h\u00fck\u00fcmlerine g\u00f6re re\u00e7ete edilebilir.\u201d   Not: Klozapin (Leponex) : En fazla bir ayl\u0131k doz olmas\u0131na ve Klozapin Gran\u00fclosit izlem formunun e-re\u00e7etede belirtilmesine dikkat edilmelidir. 4)   6.2.9.A -1De\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Eritropoietin alfa-beta-zeta, metoksipolietilen glikol epoetin beta ve darbepoetin ile tedaviye ba\u015flamadan \u00f6nce; hastan\u0131n ferritin ve\/veya transferrin saturasyonu (TSAT) de\u011ferlerine bak\u0131lacakt\u0131r. Bu de\u011ferler TSAT < %20 ve\/veya ferritin <100 \u00b5g\/L ise hastaya \u00f6ncelikle oral veya intraven\u00f6z demir tedavisine ba\u015flanacakt\u0131r. TSAT \u2265 %20 ve\/veya ferritin \u2265 100 \u00b5g\/L oldu\u011funda hemoglobin de\u011feri 10 gr\/dl alt\u0131nda ise tedaviye ba\u015flan\u0131r. Hedef hemoglobin de\u011feri 11-12 gr\/dl aras\u0131d\u0131r. Hemoglobin de\u011feri 11 gr\/dl’ye ula\u015f\u0131ncaya kadar ba\u015flang\u0131\u00e7 dozunda tedaviye devam edilir ve Hb seviyesini\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/\" \/>\n<meta property=\"og:site_name\" content=\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"article:published_time\" content=\"2013-01-25T07:13:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T08:09:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Yeni Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Yeni Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/\"},\"author\":{\"name\":\"Yeni Admin\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\"},\"headline\":\"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI\",\"datePublished\":\"2013-01-25T07:13:00+00:00\",\"dateModified\":\"2026-01-19T08:09:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/\"},\"wordCount\":3119,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"articleSection\":[\"ODA\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/\",\"name\":\"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"datePublished\":\"2013-01-25T07:13:00+00:00\",\"dateModified\":\"2026-01-19T08:09:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"contentUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2013\\\/01\\\/25\\\/sut-komisyonu-calismasi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Anasayfa\",\"item\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#website\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"contentUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"width\":635,\"height\":635,\"caption\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\",\"name\":\"Yeni Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"caption\":\"Yeni Admin\"},\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/author\\\/yeniadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/","og_locale":"tr_TR","og_type":"article","og_title":"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","og_description":"  SUT KOM\u0130SYONU \u00c7ALI\u015eMASI   Pratik Bilgiler:   Plavix tb: G\u0130S \u0130ntolerans\u0131 ibaresi kald\u0131r\u0131ld\u0131. KAH tan\u0131s\u0131nda Anjio \u015fart\u0131 devam etmektedir. Mide ila\u00e7lar\u0131: 14 tb\u2019lik formundan 2 kutu yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi zorunlulu\u011fu devam etmektedir. 30 tb lik olanlar devam re\u00e7etelerinde \u00f6denir. Bu devam re\u00e7etesinin, ilk al\u0131mdaki ila\u00e7 bitim tarihinden sonra 3 ay i\u00e7ersinde olmal\u0131d\u0131r. Anemi ila\u00e7lar\u0131: Bir kutudan fazla yaz\u0131ld\u0131\u011f\u0131nda te\u015fhis ve tedavi s\u00fcresi istenmektedir. Altuzan Amp: Ok\u00fcler neovask\u00fclarizasyonlar ve t\u00fcm makulopati veya retinopatilerde periok\u00fcler veya intraok\u00fcler olarak endikasyonu olmad\u0131\u011f\u0131 halde kullan\u0131labilmektedir.(Endikasyan D\u0131\u015f\u0131 ila\u00e7 Kullan\u0131m duyurusu) Zofran tb : Yatan Hastalarda \u00f6denir. Ayaktan Sadece Kanser veya Kan Hastal\u0131klar\u0131(alt ba\u015fl\u0131klar dahil) raporu ile \u00f6denir. Risperdal amp: Sadece yatan hastalarda Psikiyatri uzman\u0131nca veya yine bu uzman hekimin bulundu\u011fu sa\u011fl\u0131k kurulu raporuyla. Helicol 15 mg 30 tb: ilk defa kullan\u0131ld\u0131\u011f\u0131nda \u00f6denmez. Devam re\u00e7etelerinde rapor \u015fart\u0131 aranmaks\u0131z\u0131n Helicol 15 mg 30 tb \u00f6denir. Piogtan 30 mg 30 tb:\u0130lk defa re\u00e7ete edildi\u011finde 28 tb lik e\u015fde\u011feri oldu\u011fundan \u00f6denmez. Ancak devam re\u00e7etesinde ila\u00e7 bitiminden sonra 3 ay i\u00e7ersinde hasta taraf\u0131ndan re\u00e7ete edildi\u011finde Piogtan 30 mg 30 tb lik \u00f6denir. Sevk \u0130\u015flemi:Kurum Mart 2013 itibariyle e-sevk uygulamas\u0131na ge\u00e7ecektir. Kurum duyuru yap\u0131ncaya kadar sevk \u00f6rne\u011finin bir n\u00fcshas\u0131 al\u0131nacakt\u0131r. E-Sevk i\u015flemlerinde uygulamaya ge\u00e7i\u015fte ya\u015fanabilecek olas\u0131 s\u0131k\u0131nt\u0131lar\u0131n \u00f6nlenmesi i\u00e7in sa\u011fl\u0131k hizmeti sunucular\u0131n\u0131n a\u015fa\u011f\u0131da belirtilen hususlara dikkat etmesi gerekmektedir. M\u00fcstahakl\u0131k sorgulamas\u0131 60\/c-1, 60\/c-3 veya 60\/c-9 bilgisi d\u00f6nen hastalar ile Sa\u011fl\u0131k Uygulama Tebli\u011finde sa\u011fl\u0131k hizmeti sunucular\u0131na m\u00fcracaat i\u00e7in sevk zinciri tan\u0131mlanm\u0131\u015f ki\u015filerin sevk i\u015flemlerinde, sisteme entegrasyonu sa\u011flan\u0131ncaya kadar \u00f6nceki uygulamalara devam edilecektir. Enbrel,Leponex tb,Roaccutan: Kurum taraf\u0131ndan yap\u0131lacak olan duyuruya kadar Enbrel i\u00e7in hasta onaylama formu ile G\u00fcvenlik izlem formu re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecek. Leponex i\u00e7in Gran\u00fclosit izlem formu(L\u00f6kosite bak\u0131lm\u0131\u015f olan) ve Roacccutan i\u00e7in hasta onaylama formlar\u0131 re\u00e7ete \u00e7\u0131kt\u0131s\u0131na eklenecektir. Enfeksiyon Hastal\u0131klar\u0131 Uzaman\u0131\u0131 onay\u0131: Hastanenin kendi i\u00e7 sistemiyle ilgili olup hen\u00fcz medullada g\u00f6r\u00fcnmemektedir. Kurum gerekli duyuruyu yap\u0131ncaya kadar Ma\u011fduriyet olu\u015fmamas\u0131 i\u00e7in dikkat edilmesi gerekmektedir.   10.01.2013 Tarihli SUT De\u011fi\u015fikli\u011fi   1)   6.1.4- 5.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) : Yan\u0131klar, anemiler, sistemik olmayan mantar enfeksiyonlar\u0131, refl\u00fc ve GIS \u00fclserlerinde kullan\u0131lan ila\u00e7lar; yaln\u0131z dermatoloji uzman hekimlerince re\u00e7ete edilebilen oral retinoidler, taburcu edilen hastalar\u0131n idame tedavisi i\u00e7in d\u00fczenlenen re\u00e7etelere yaz\u0131lan ila\u00e7lar, en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir.   6.1.4- 8.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Hastan\u0131n tedavisinde ilk defa re\u00e7ete edilecek ila\u00e7lar (raporlu olsa dahi) en fazla 28 g\u00fcnl\u00fck doza kadar \u00f6denir. Sonraki re\u00e7etelerde yaz\u0131lacak ila\u00e7 miktar\u0131 i\u00e7in tebli\u011fde yer alan genel veya \u00f6zel d\u00fczenlemeler esas al\u0131n\u0131r. Bu ila\u00e7lar\u0131n devam re\u00e7etelerindeki farkl\u0131 farmas\u00f6tik dozlar\u0131 da ilk tedavi olarak kabul edilir. Not: Bir ila\u00e7 ilk defa re\u00e7ete edildi\u011finde, ilac\u0131n veya e\u015fde\u011firinin k\u00fc\u00e7\u00fck formunun verilmesine dikkat ediniz. Ancak tedavi \u015femas\u0131nda fazla say\u0131da i\u00e7eren ilac\u0131n kullan\u0131m\u0131nda, 28 g\u00fcnl\u00fck dozu ge\u00e7miyor ise yine verilebilir. Paxil 56 tb 2*1 den 56 tb lik form \u00f6denir. Paxil 56 tb 1*1 \u015feklinde yaz\u0131l\u0131 ise 28 tb lik formu \u00f6denir. Devam re\u00e7etelerinde ise 28 g\u00fcnl\u00fck k\u0131s\u0131tlamas\u0131 yoktur. \u00d6rnek olarak piogtan 30 mg 30 tb ilk defa hasta kullanacak ise e\u015fde\u011fi olan actos 30 mg 28 tb verilmelidir. Devam\u0131nda ise piogtan 30 mg 30 tb 3 ayl\u0131k 01.02.2013 tarihinden itibaren ise 6 ayl\u0131k verilebilir. Rapor yenilenmesinde ilac\u0131n dozunda de\u011fi\u015fiklik yok ise devam gibi kabul edilir 3 ayl\u0131k veya a\u015fa\u011f\u0131da belirtilen hastal\u0131klarda 6 ayl\u0131k alabilir.             2)   6.1.5- 9.F\u0131kraEklenmi\u015ftir (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) \u201c(9) Yeniden e-re\u00e7ete d\u00fczenlenmeksizin yap\u0131lacak ila\u00e7 temininde; a) SUT eki \u201cHasta Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar Listesi\u2019nde (EK-2) yer alan hastal\u0131klardan a\u015fa\u011f\u0131da belirtilen hastal\u0131k gruplar\u0131 ile bu hastal\u0131k gruplar\u0131 i\u00e7in EK-2 listesinde tan\u0131ml\u0131 ila\u00e7lar uygulama kapsam\u0131ndad\u0131r. 1- (4.1.) Kalp Yetmezli\u011fi (I50) 2- (4.2.) Koroner Arter Hastal\u0131\u011f\u0131 (I20) (I25) (Z95.1) (Z95.5-Z95.9) 3- (4.5.) Arteriyel hipertansiyon (I10 -I13) (I15) 4- (4.8.) Hiperkolesterolemi*, hiperlipidemi * (E78) 5- (7.2.1.) Diabetes Mellitus (E10 \u2013 E14) 6- (10.3.1.) Parkinson hastal\u0131\u011f\u0131 (G20) 7- (10.7.) Demans (F00) (F01.1 \u2013 F01.9) (F02-F03) (G30) 8- (12.1.) Glokom (H40.1-H40.9) 9- (12.2) Kronik ve n\u00fckseden \u00fcveitler, tiroide ba\u011fl\u0131 oftalmopati ve sempatik oftalmi, keratoplasti red reaksiyonu (H20.1) (H20.8) (H06.2) (H44.1) (T86.8-T86.9) 10- (12.3.) Kuru g\u00f6z sendromu (H04.1) b) Yukar\u0131da belirtilen hastal\u0131klarda sa\u011fl\u0131k raporuna dayan\u0131larak d\u00fczenlenmi\u015f re\u00e7eteye istinaden yeniden re\u00e7ete d\u00fczenlenmeksizin eczaneden ila\u00e7 temin edilebilir. Bu \u015fekilde ila\u00e7 temini, d\u00fczenlenmi\u015f re\u00e7ete tarihi itibariyle 6 ayl\u0131k s\u00fcreyi kapsar. S\u00fcre bitiminde tekrar re\u00e7ete d\u00fczenlenir. c) 6 ay boyunca, d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 miktarlar esas al\u0131narak, yeniden re\u00e7ete d\u00fczenlenmeksizin bu miktarlarda ila\u00e7 temin edilebilir. Ancak SUT \u2019ta belirtilen \u00f6zel h\u00fck\u00fcmler ile d\u00fczenlenmi\u015f re\u00e7etede yaz\u0131l\u0131 g\u00fcnl\u00fck kullan\u0131m dozuna g\u00f6re bir seferde \u00fc\u00e7 ayl\u0131k tedavi dozunun a\u015f\u0131lmamas\u0131 g\u00f6zetilir. \u00e7) Raporun ge\u00e7erlilik s\u00fcresinin bitmesi durumunda yeniden rapor ve re\u00e7ete d\u00fczenlenmesi \u015fart\u0131 aran\u0131r.\u201d Not: b ve C maddelerine dikkat edilirse, 6 ayl\u0131k doz ile 3 ayl\u0131k doz uygulamalar\u0131n\u0131 g\u00f6rmekteyiz. 6 ayl\u0131k doz uygulamas\u0131 sadece yukar\u0131da belirtilen hastal\u0131klarda uygulanacakt\u0131r. Rapor tarihi ila\u00e7 verilme tarihinden sonra 6 aydan \u00f6nce bitiyor ise bu s\u00fcreye kadar verilir. Dikkat edilmesi gereken di\u011fer husus ise; bir ilac\u0131n 28 g\u00fcnl\u00fck dozundan 3 ayl\u0131k 4 kutu yaz\u0131lm\u0131\u015f ise 3 kutu yerine 4 kutu da verilebilme imkan\u0131n\u0131n sa\u011flanmas\u0131d\u0131r. Singulair 28 tb 1*1 den rapor s\u00fcresi dahilinde 4 kutu \u00f6denir.   3)   6.2.2- 2. ve 3.F\u0131kraDe\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) \u201c(2) Yeni nesil (atipik) antipsikotiklerin (klozapin, olanzapin, risperidon, amis\u00fclpirid, ketiapin, ziprosidon, aripiprazol, zotepine, Sertindol, paliperidon ) ve kombinasyonlar\u0131n\u0131n oral formlar\u0131, psikiyatri veya n\u00f6roloji uzman hekimleri taraf\u0131ndan veya bu hekimlerce d\u00fczenlenecek uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Klozapin en fazla 1 ayl\u0131k dozda re\u00e7ete edilebilir. (3) Yeni nesil (atipik) antipsikotiklerin parenteral formlar\u0131 psikiyatri uzman hekimi veya bu uzman hekim taraf\u0131ndan d\u00fczenlenen uzman hekim raporuna dayan\u0131larak t\u00fcm hekimlerce re\u00e7ete edilebilir. Bu grup antipsikotiklerden risperidon ve paliperidonun parenteral formlar\u0131 ise Ek:2\/B h\u00fck\u00fcmlerine g\u00f6re re\u00e7ete edilebilir.\u201d   Not: Klozapin (Leponex) : En fazla bir ayl\u0131k doz olmas\u0131na ve Klozapin Gran\u00fclosit izlem formunun e-re\u00e7etede belirtilmesine dikkat edilmelidir. 4)   6.2.9.A -1De\u011fi\u015fikli\u011fi (Y\u00fcr\u00fcrl\u00fcl\u00fck Tarihi 18.01.2013) Eritropoietin alfa-beta-zeta, metoksipolietilen glikol epoetin beta ve darbepoetin ile tedaviye ba\u015flamadan \u00f6nce; hastan\u0131n ferritin ve\/veya transferrin saturasyonu (TSAT) de\u011ferlerine bak\u0131lacakt\u0131r. Bu de\u011ferler TSAT < %20 ve\/veya ferritin <100 \u00b5g\/L ise hastaya \u00f6ncelikle oral veya intraven\u00f6z demir tedavisine ba\u015flanacakt\u0131r. TSAT \u2265 %20 ve\/veya ferritin \u2265 100 \u00b5g\/L oldu\u011funda hemoglobin de\u011feri 10 gr\/dl alt\u0131nda ise tedaviye ba\u015flan\u0131r. Hedef hemoglobin de\u011feri 11-12 gr\/dl aras\u0131d\u0131r. Hemoglobin de\u011feri 11 gr\/dl’ye ula\u015f\u0131ncaya kadar ba\u015flang\u0131\u00e7 dozunda tedaviye devam edilir ve Hb seviyesini","og_url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/","og_site_name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","article_published_time":"2013-01-25T07:13:00+00:00","article_modified_time":"2026-01-19T08:09:57+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","type":"image\/png"}],"author":"Yeni Admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Yeni Admin","Tahmini okuma s\u00fcresi":"16 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#article","isPartOf":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/"},"author":{"name":"Yeni Admin","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120"},"headline":"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI","datePublished":"2013-01-25T07:13:00+00:00","dateModified":"2026-01-19T08:09:57+00:00","mainEntityOfPage":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/"},"wordCount":3119,"commentCount":0,"publisher":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#primaryimage"},"thumbnailUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","articleSection":["ODA"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/","url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/","name":"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","isPartOf":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#primaryimage"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#primaryimage"},"thumbnailUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","datePublished":"2013-01-25T07:13:00+00:00","dateModified":"2026-01-19T08:09:57+00:00","breadcrumb":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#primaryimage","url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","contentUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2013\/01\/25\/sut-komisyonu-calismasi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Anasayfa","item":"https:\/\/sanliurfaeo.birodam.org.tr\/"},{"@type":"ListItem","position":2,"name":"SUT KOM\u0130SYONU \u00c7ALI\u015eMASI"}]},{"@type":"WebSite","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#website","url":"https:\/\/sanliurfaeo.birodam.org.tr\/","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","description":"","publisher":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sanliurfaeo.birodam.org.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Organization","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","url":"https:\/\/sanliurfaeo.birodam.org.tr\/","logo":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/logo\/image\/","url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","contentUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","width":635,"height":635,"caption":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120","name":"Yeni Admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","caption":"Yeni Admin"},"url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/author\/yeniadmin\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts\/4924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/comments?post=4924"}],"version-history":[{"count":0,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts\/4924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/media\/191"}],"wp:attachment":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/media?parent=4924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/categories?post=4924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/tags?post=4924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}